Gilead And CAR-T Of Solid Tumors: The Next Revolution In Cancer Therapeutics
- Gilead has thus far shown little inclination to develop its onco portfolio.
- However, the onco space is one that can offer a good replacement option for its HCV franchise.
- This article discusses how the CAR-T in solid tumor space can be one acquisition idea.
By Dr. Udaya K Maiya, MBBS, MD, DNB, DCCF-Paris
The full post is available to investor members only. Subscribe here.